- Home
- CMMB vs IGC Comparison
CMMB vs IGC Comparison
Compare CMMB & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- IGC
- Stock Information
- Founded
- CMMB 2004
- IGC 2005
- Country
- CMMB Israel
- IGC United States
- Employees
- CMMB N/A
- IGC N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- IGC Health Care
- Exchange
- CMMB Nasdaq
- IGC Nasdaq
- Market Cap
- CMMB 23.0M
- IGC 20.2M
- IPO Year
- CMMB N/A
- IGC N/A
- Fundamental
- Price
- CMMB $1.32
- IGC $0.30
- Analyst Decision
- CMMB Strong Buy
- IGC Strong Buy
- Analyst Count
- CMMB 2
- IGC 2
- Target Price
- CMMB $8.50
- IGC $3.88
- AVG Volume (30 Days)
- CMMB 133.3K
- IGC 211.4K
- Earning Date
- CMMB 05-15-2025
- IGC 06-23-2025
- Dividend Yield
- CMMB N/A
- IGC N/A
- EPS Growth
- CMMB N/A
- IGC N/A
- EPS
- CMMB N/A
- IGC N/A
- Revenue
- CMMB N/A
- IGC $1,236,000.00
- Revenue This Year
- CMMB N/A
- IGC N/A
- Revenue Next Year
- CMMB N/A
- IGC $16.45
- P/E Ratio
- CMMB N/A
- IGC N/A
- Revenue Growth
- CMMB N/A
- IGC 1.65
- 52 Week Low
- CMMB $0.78
- IGC $0.25
- 52 Week High
- CMMB $2.55
- IGC $0.55
- Technical
- Relative Strength Index (RSI)
- CMMB 50.02
- IGC 45.68
- Support Level
- CMMB $1.22
- IGC $0.30
- Resistance Level
- CMMB $1.38
- IGC $0.32
- Average True Range (ATR)
- CMMB 0.08
- IGC 0.02
- MACD
- CMMB -0.01
- IGC -0.00
- Stochastic Oscillator
- CMMB 40.00
- IGC 19.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.